Trial Profile

Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibudilast (Primary)
Indications Amyotrophic lateral sclerosis
Focus Expanded access; Therapeutic Use
Acronyms SEANOBI-ALS

Most Recent Events

08 Apr 2025 According to a MediciNova media release, the company announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial. This significant milestone marks the beginning of a critical trial aimed at providing access to MN-166 for ALS patients who are not eligible for the ongoing Phase 2/3 COMBAT-ALS trial.
08 Apr 2025 Status changed from planning to recruiting, according to a MediciNova media release.
04 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com